RAASestäjillä

RAASestäjillä is a Finnish term referring to drugs that inhibit the renin-angiotensin-aldosterone system (RAAS). This system is a crucial hormonal cascade that regulates blood pressure and fluid balance in the body. When activated, the RAAS leads to the production of angiotensin II, a potent vasoconstrictor, and aldosterone, which promotes sodium and water retention. These effects contribute to increased blood pressure.

RAAS inhibitors are a class of medications commonly prescribed for conditions such as hypertension (high blood pressure), heart failure, and chronic kidney disease. By blocking different components of the RAAS, these drugs help to lower blood pressure, reduce the workload on the heart, and protect the kidneys.

The main categories of RAAS inhibitors include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, and aldosterone antagonists. ACE inhibitors block the enzyme responsible for converting angiotensin I to angiotensin II. ARBs directly block the action of angiotensin II by preventing it from binding to its receptors. Direct renin inhibitors block the very first step of the RAAS by inhibiting renin. Aldosterone antagonists block the effects of aldosterone.

These medications are generally well-tolerated, but like all drugs, they can have side effects. Common side effects can include a dry cough (with ACE inhibitors), dizziness, and elevated potassium levels. Their use requires medical supervision and regular monitoring by a healthcare professional to ensure effectiveness and manage potential adverse reactions.